BioCentury | Jan 20, 2021

IPO queue bulges further as Adagene, NexImmune are among latest to file

After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings. The pair joined seven therapeutics developers...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | Jan 12, 2021
Product Development

OX40L pipeline: Data Byte

Kymab leads the pack among companies targeting OX40L for autoimmune disorders, while Moderna has the most advanced program against the target for cancer.  OX40L, the ligand for the OX40 receptor, is expressed on activated antigen-presenting...
BioCentury | Jan 9, 2021

4Q20 Wrap: Stocking up

Life sciences stocks continued an upward trajectory at the end of 2020, with median gains of at least 7% in 4Q20 and at least 24% over the year across all market cap tiers. Companies valued...
BioCentury | Dec 12, 2020

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

In its December opinions, EMA’s CHMP recommended a restriction for Gilead’s Veklury, specifying that COVID-19 patients should be on low- or high-flow oxygen or other non-invasive ventilation at the start of treatment.  The committee also...
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

The COVID R&D Alliance is looking beyond the imminent rollout of vaccines, anticipating an ongoing need for effective therapies in hospitalized COVID-19 patients. Last week, it launched the COMMUNITY...
BioCentury | Dec 8, 2020
Product Development

Dec. 7 ASH Quick Takes: CRISPR, Vertex update durability for edited cell therapy; plus J&J- Legend, Kura, Fate, Pfizer, Autolus and Affimed

Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) showed seven transfusion-dependent β thalassemia patients in the CLIMB-Thal-111 study remain transfusion-free for up to 18 months following CTX001...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

DISEASE CATEGORY: Ophthalmic disease INDICATION: Ocular hypertension Penn researchers showed that NLY01 from Neuraly Inc., could treat ocular hypertension. In mice modelling ocular hypertension, the pegylated exenatide reduced retinal ganglion cell death and mRNA levels of...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
Items per page:
1 - 10 of 3334